Earnings Call Intelligence Subscribe
Home › Call Sheets › ABT › Q4'25
Call sheet · Q4'25

Abbott Laboratories (ABT)

Q4'25 earnings call · held January 22, 2026 · compared with the Q3'25 call · management-credibility review
9/12
Disclosure score
2 medium, 4 low flags
Financial quality
Bottom line
The sleeper story is Core Lab Diagnostics quietly building momentum for a 2026 acceleration while everyone obsesses over CGM deceleration fears and nutrition drama. Three consecutive quarters of acceleration plus VBP headwinds lapping sets up mid-to-high single digit growth in a $4+ billion segment. Meanwhile, Ford's admission that nutrition pricing was 'not sustainable long-term' and forced shift to volume-driven growth reveals classic CPG margin pressure. The binding constraint isn't demand (CGM still adding $1B annually, devices growing double digits) but execution bandwidth as they simultaneously fix nutrition, integrate Exact Sciences, and launch multiple new products. Ford: 'We could have gone a couple more quarters doing this, but it would not be sustainable.' My view changes if Q1 2026 nutrition volumes don't recover or if Core Lab diagnostics fails to show the promised acceleration.

The 30-second version

  • Nutrition business forced into price cuts to salvage volumes - classic CPG death spiral
  • CGM adding $1B annually for third straight year despite 'slowing market' narrative
  • Core Lab Diagnostics quietly accelerating while everyone obsesses over China

What changed this quarter

MetricQ3'25Q4'25Change
Revenue$10.6B (+5.5% organic ex-COVID)$11.2B (+3.8% organic ex-COVID)Decelerated 170 bps despite easier comps
Adjusted EPS$1.30 (+high single digits)$1.50 (+12%)Accelerated to double digits
Operating Margin23.0% (+40 bps)25.8% (+150 bps)Margin expansion accelerated 110 bps
Medical Devices Revenue+12.5%+10.5%Decelerated 200 bps
CGM Sales$2.0B (+17%)Q4 +12%, FY +17%Quarterly growth moderated but annual consistent
Nutrition Revenue+4%DeclinedTurned negative after 4% growth
Diagnostics RevenueModest growth ex-COVID+3.5% ex-COVIDSlight acceleration
Core Lab Diagnostics7% ex-China3.5%, accelerating for 3rd quarterMomentum building despite headline decel
EPD Revenue+7%+7%Maintained high single digit growth
ElectrophysiologyDouble digit growthDouble digit in US and internationallySustained double digit momentum

Accountability tracked

7 new promises made4 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full ABT Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.